Margalit, O., Harmsen, W., Shacham-Shmueli, E., Voss, M., Boursi, B., Cohen, R., Olswold, C., Saltz, L., Hurwitz, H., Adams, R.  ORCID: https://orcid.org/0000-0003-3915-7243, Chibaudel, B., Grothey, A., Yoshino, T., Zalcberg, J., de Gramont, A., Shi, Q. and Lenz, H.
2022.
P-106 Evaluating sex as a predictive marker for response to bevacizuamb in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database.
Annals of Oncology
33
(S4)
, S287-S287.
10.1016/j.annonc.2022.04.196
|
Abstract
Background Previous studies suggest a possible sex-specific response to bevacizumab in metastatic colorectal carcinoma, showing a benefit in males, while the effect in females is less significant. Therefore, we evaluated response to bevacizumab according to sex. Methods Data from 3369 metastatic colorectal carcinoma patients enrolled on four first-line randomized trials testing chemotherapy with or without bevacizumab (2000-2007) were pooled. Association between sex and progression-free survival and overall survival was evaluated by stratified Cox regression model, adjusted for potential confounders. Predictive value was evaluated by interaction effect between sex and treatment. In a pre-planned secondary analysis, analyses were stratified using an age cut-point of 60 years to evaluate the possible role of menopausal-related effects. Results Median overall survival was not statistically different between males and females in the entire study population (18.8 vs. 17.6 months, respectively; adjusted hazard ratio=0.92, 95% CI=0.84-1.02, p=0.11). Bevacizumab was associated with an improved median overall survival in males and females, with a 2.3- and 0.6-months benefit, respectively, as well as an improved progression-free survival (2.0 and 1.9-months benefit, respectively). Stratified by age, bevacizumab resulted in improved progression-free survival and overall survival in males at both age categories. In females at or above the age of 60 (n=731), bevacizumab resulted in improved progression-free survival and overall survival. However, in females below the age of 60 (n=634), overall survival benefit did not reach statistical significance (adjusted hazard ratio=0.94, 95% CI 0.74-1.20). Conclusions Our results confirmed the median overall survival benefit from addition of bevacizumab to first-line chemotherapy in metastatic colorectal carcinoma in both sexes. Among females, the benefit was less than 1 month. For females under the age of 60, there was no overall survival benefit.
| Item Type: | Article |
|---|---|
| Date Type: | Publication |
| Status: | Published |
| Schools: | Medicine |
| Additional Information: | License information from Publisher: LICENSE 1: URL: http://creativecommons.org/licenses/by-nc-nd/4.0/, Start Date: 2023-07-02 |
| Publisher: | Elsevier |
| ISSN: | 0923-7534 |
| Last Modified: | 10 Nov 2022 11:35 |
| URI: | https://orca.cardiff.ac.uk/id/eprint/151078 |
Actions (repository staff only)
 |
Edit Item |
Altmetric
Altmetric
Cardiff University Information Services